Why plasma-derived factor VIII?

TY - JOUR

T1 - Why plasma-derived factor VIII?

AU - Aledort, Louis

AU - Carpenter, Shannon L.

AU - Cuker, Adam

AU - Kulkarni, Roshni

AU - Recht, Michael

AU - Young, Guy

AU - Leissinger, Cindy

N1 - Funding Information: LA is a chairman of SAC‐Kedrion, DSMB‐Chair of Octapharma post licensing, DSMB—Shire member post licensing. SC is a self speaker of Ameriacn Academy of Peditarics, Impact Education (NHF), CSL Behring, Nationwide Children‘s Hospital. A self consultant services in Kedrion Biopharmaceuticals, HEMA Biologics, Novo Nordisk Pharmaceuticals,Inc.Aselfexpertwitnessservices,medicalmalprac-tice work in Kane County State‘s Attorney and 4th Judicial District Attorney‘s Office—Colorado. A self advisory board, review panel participant in Genentech Incorporated, Kedrion Pharmaceuticals and in American Academy of Pediatrics. RK is a member of advisory boards in Bioverativ, BPL, Genentech, Kedrion, Novo Nordisk, Octapharma, Shire. Also a member of clinical trials in Bioverativ, Bayer, Biomarin, Shire and Novo Nordisk. MR has received research funding payed to his institution from Bioverative/Sanofi, Genentech, NovoNordisk, Shire, Spark Therapeutics, and uniQure. In addition, he has served as a paid consultant to Bioverative/Sanofi, CSL Behring, Genentech, Kedrion, NovoNordisk, Pfizer, Shire and uniQure. CL has received compensation for participation in advisory boards for Bayer, Biogen, CSL, Behring, HemaBiologics, Kedrion, Novo Nordisk, Pfizer, Roche and Shire, and has received research funding from Biomarin and Roche.

PY - 2019/5

Y1 - 2019/5

UR - http://www.scopus.com/inward/record.url?scp=85062986155&partnerID=8YFLogxK

U2 - 10.1111/hae.13705

DO - 10.1111/hae.13705

M3 - Letter

C2 - 30866124

AN - SCOPUS:85062986155

SN - 1351-8216

VL - 25

SP - e183-e185

JO - Haemophilia

JF - Haemophilia

IS - 3

ER -